Taxane

Phase 3Small molecule

Bristol-Myers Squibb

Taxane is one of 204 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

203

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Gastric CancerActive, not recruiting

Cervical CancerActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Esophageal AdenocarcinomaPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Gastric CancerPhase 2/Phase 3

Active, not recruiting

Cervical CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Taxane

Bristol-Myers Squibb

Phase 3

7 2

Halaven

Eisai

Preclinical

38 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

MS Contin

Merck & Co.

Preclinical

2 6

Voltaren

Novartis

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Zinecard

CChildren's Oncology Group

Preclinical

2 9

Acupan

YYonsei University

Preclinical

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Advanced or Metastatic Solid Tumors

NCT07158918

Q2 2028

Phase 2Recruiting

Breast Cancer

NCT06102824

Q4 2029

Phase 3Active, not recruiting

Breast Cancer

NCT04784715

Q1 2033

Phase 2Active, not recruiting

Breast Cancer

NCT04293393

Clinical

Trials by Indication[1]

Breast Cancer7 trials

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04784715·1,157 enrolled

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruiting·SSpanish Breast Cancer Research Group·Phase 2·NCT04293393·200 enrolled

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Withdrawn·PPeregrine Pharmaceuticals·Phase 2/3·NCT02651610

Show 4 more trials

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Withdrawn·PPeregrine Pharmaceuticals·Phase 2·NCT02685306

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

Active, not recruiting·YYonsei University·Phase 3·NCT02441933·878 enrolled

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06102824·252 enrolled

A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00475670·44 enrolled

Ovarian Cancer2 trials

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Terminated·MMorphotek·Phase 3·NCT00849667·1,100 enrolled

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

Advanced Cancer2 trials

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00332748·36 enrolled

A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00326131·6 enrolled

Randomized1 trial

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

Completed·NNew Mexico Cancer Research Alliance·Phase 3·NCT00277043·200 enrolled

Advanced or Metastatic Solid Tumors1 trial

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Recruiting·AABL Bio, Inc.·Phase 1/2·NCT07158918·65 enrolled

6 more indications

Esophageal Adenocarcinoma1 trial

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

Completed·—··NCT04920747·65 enrolled

Non-Small Cell Lung Cancer1 trial

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00103831

Lymphoma1 trial

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Completed· Bayer logo

Bayer·Phase 2·NCT00044551·29 enrolled

Biomarkers1 trial

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated·UUniversity of Wisconsin, Madison··NCT03393741·5 enrolled

Cervical Cancer1 trial

Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)

Unknown status·SSun Yat-sen University·N/A·NCT02624531·60 enrolled

Gastric Cancer1 trial

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Terminated· Roche logo

Roche·Phase 2/3·NCT01641939·415 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Taxane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Taxane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Taxane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Taxane

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q4 2029

Q1 2033

Trials by Indication[1]

Breast Cancer7 trials

Ovarian Cancer2 trials

Advanced Cancer2 trials

Randomized1 trial

Advanced or Metastatic Solid Tumors1 trial

Esophageal Adenocarcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Lymphoma1 trial

Biomarkers1 trial

Cervical Cancer1 trial

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News